Codagenix Inc. announced that the U.S. Department of Defense (DoD), through the U.S. Army Medical Research and Development Command and the U.S. Army Medical Research Acquisition Activity, has awarded the company $5.88 million to advance the development of its Codavax-Denv, a tetravalent live attenuated dengue vaccine program.
Appili Therapeutics Inc. has secured a commitment for the second stage of funding for ATI-1701 from the U.S. Air Force Academy (USAFA), who is working in partnership with the Defense Threat Reduction Agency, the funding agency.
The U.S. FDA cleared Pfizer Inc.’s Penbraya (meningococcal groups A, B, C, W and Y vaccine), the first pentavalent shot designed to provide coverage against the most common serogroups causing meningococcal disease in adolescents and young adults through age 25.
The World Health Organization recently endorsed an economical malaria vaccine with a 75% effectiveness rate, which costs less than half of the initial vaccine (RTS,S/AS01) created two years ago. The new vaccine, R21/Matrix-M, developed by the University of Oxford and the Serum Institute of India, marks a significant milestone after decades of scientific research.
Vaxcyte Inc. has received FDA clearance of its IND application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease.
As COVID-19 vaccine development continues, the U.S. FDA is releasing a revised version of its 2020 guidance, “Development and licensure of vaccines to prevent COVID-19.”
At the IDWeek 2023 infectious disease conference held last week in Boston, fungal infections got the audience’s attention during the session titled, “The antifungal evolution: novel strategies for a changing world.” With the emergence of some resistant pathogens such Candida auris and the growing disease burden in the population at risk for life-threatening fungal infections, these pathogens are more than ever standing out within the infectious diseases arena.
The official end of the COVID-19 public health emergency in the U.S. in May did not mark the end of interest and investment in the area. In the shifting landscape, attention has pivoted to new markets, emerging strains, boosters, and the commercialization and distribution of COVID-19 vaccines and therapies.
The vagaries of the COVID-19 market and the uncertainties of pandemic fatigue are hitting some biopharma companies in the pocketbook, at least for now. Due to lower-than-expected revenues from its COVID-19 Comirnaty vaccine and antiviral Paxlovid (nirmatrelvir/ritonavir), Pfizer Inc. reduced its 2023 revenue guidance by $9 billion after hours Oct. 13, saying it now anticipates full-year 2023 revenues to range from $58 billion to $61 billion – down from its previous guidance range of $67 billion to $70 billion.
In the U.S., hospital-borne antimicrobial-resistant nosocomial infections affect over 700,000 people every year causing more than 90,000 deaths along with a $28-45 billion financial burden. This commonly involves either methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus or carbapenem-resistant Acinetobacter baumannii.
RSS
